ALIOY - ACTELION LTD

Other OTC - Other OTC Delayed Price. Currency in USD
70.00
0.00 (0.00%)
At close: 3:55PM EST
Stock chart is not supported by your current browser
Previous Close70.00
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters3 months ago

    J&J takes $13.6 billion charge related to new U.S. tax law

    Also on Tuesday, U.S. appeals court upheld a ruling that invalidated a crucial J&J patent on its blockbuster rheumatoid arthritis drug Remicade. U.S. President Donald Trump signed the new U.S. tax law late last year, and many large U.S. corporations and drugmakers have said they will take advantage of its new, lower tax rate on repatriated foreign earnings and cash. J&J reported a year ago that it had $66 billion in undistributed international earnings and on Tuesday said it had $16 billion in cash outside the United States.

  • Why 2017 Was a Year to Remember for Johnson & Johnson
    Motley Fool4 months ago

    Why 2017 Was a Year to Remember for Johnson & Johnson

    Three keys behind the healthcare giant's tremendous year in 2017 that could be critical for next year also.

  • Reuters5 months ago

    Idorsia to get $230 million from J&J in latest hypertension deal

    Idorsia (IDIA.S), the Swiss drugmaker spun off from Actelion after it was bought by Johnson & Johnson (J&J) (JNJ.N), will receive a one-time payment of $230 million (171 million pounds)from J&J's Janssen unit as they partner on aprocitentan for resistant hypertension. Aprocitentan is a metabolite of Actelion's Opsumit. Idorsia and J&J are seeking to develop it to treat hypertension patients whose disease has failed at least three therapies.

  • Reuters5 months ago

    Idorsia to get $230 mln from J&J in latest hypertension deal

    Idorsia, the Swiss drugmaker spun off from Actelion after it was bought by Johnson & Johnson (J&J), will receive a one-time payment of $230 million from J&J's Janssen unit as they partner on aprocitentan for resistant hypertension. Aprocitentan is a metabolite of Actelion's Opsumit. Idorsia and J&J are seeking to develop it to treat hypertension patients whose disease has failed at least three therapies.

  • Genmab and J&J 'love' partnership as some ponder takeover
    Reuters5 months ago

    Genmab and J&J 'love' partnership as some ponder takeover

    Genmab was Europe's second biggest biotech company, until its partner Johnson & Johnson bought Switzerland's Actelion for $30 billion (£22.30 billion) this year and propelled the Danish antibody specialist to the top spot. Now some investors wonder if the same fate might await Genmab, worth $12 billion, given the soaraway success of its blood cancer drug Darzalex. J&J sells the drug and pays Genmab a royalty of 12 to 20 percent.

  • Johnson & Johnson Q3 2017 Earnings Conference Call Transcript (JNJ)
    Motley Fool6 months ago

    Johnson & Johnson Q3 2017 Earnings Conference Call Transcript (JNJ)

    JNJ earnings call for the period ending September 30, 2017

  • New cancer drugs help Johnson & Johnson top profit estimates
    Reuters6 months ago

    New cancer drugs help Johnson & Johnson top profit estimates

    Shares of J&J, part of the Dow Jones Industrial Average, rose 3.4 percent to $140.79 on Tuesday. Guggenheim Securities analyst Tony Butler said the stock has historically done well when its high-margin pharmaceuticals business is the main driver of growth, rather than its consumer segment. Sales at J&J's pharmaceuticals segment rose 15.4 percent to $9.7 billion in the third quarter.

  • Johnson & Johnson Jumps on Pharma Strength
    Motley Fool6 months ago

    Johnson & Johnson Jumps on Pharma Strength

    Find out the key reason why the healthcare conglomerate is more optimistic than ever.

  • J&J (JNJ) Beats on Q3 Earnings, Actelion Buyout Drives Sales
    Zacks6 months ago

    J&J (JNJ) Beats on Q3 Earnings, Actelion Buyout Drives Sales

    J&J (JNJ) reported better-than-expected third-quarter 2017 results and raised its 2017 sales and profit outlook.

  • CNBC6 months ago

    Pharma business, Actelion buy drive J&J's profit beat

    J&J, which completed its $30 billion acquisition of Swiss biotech Actelion in June, reported a 11.9 percent fall in quarterly profit as costs rose.

  • Reuters6 months ago

    New cancer drugs help J&J top profit estimates

    Johnson & Johnson posted better-than-expected third-quarter earnings, raising its full-year forecast due to growth from new cancer drugs and high-margin treatments picked up in its $30 billion acquisition of Actelion earlier this year. Shares of J&J, part of the Dow Jones Industrial Average , rose 3.4 percent to $140.79 on Tuesday. Guggenheim Securities analyst Tony Butler said the stock has historically done well when its high-margin pharmaceuticals business is the main driver of growth, rather than its consumer segment.

  • 3 Questions You Need to Ask Ahead of Johnson & Johnson's Third-Quarter Report
    Motley Fool6 months ago

    3 Questions You Need to Ask Ahead of Johnson & Johnson's Third-Quarter Report

    This report will be about a lot more than just a headline sales and profit figure.

  • Forbes6 months ago

    What Factors Will Drive Johnson & Johnson's Q3 Earnings?

    Johnson & Johnson will report its Q3 2017 earnings on October 17, and we expect the company to post solid numbers, owing to three primary factors – a ramp up in key oncology drug sales, the Actelion acquisition, and forex gains.

  • CNBC6 months ago

    J&J shares upgraded by Wells Fargo, which says the third quarter was 'turning point' for stock

    Wells Fargo raises its rating on Johnson & Johnson, saying that improved performance could lead to better-than-expected third-quarter results.

  • The Smartest Move Johnson & Johnson Has Made All Year
    Motley Fool7 months ago

    The Smartest Move Johnson & Johnson Has Made All Year

    Abandoning its hepatitis C drug-development program should pay long-term dividends.

  • J&J (JNJ) PAH Drug's U.S. Label Expanded for Pediatric Use
    Zacks7 months ago

    J&J (JNJ) PAH Drug's U.S. Label Expanded for Pediatric Use

    Johnson & Johnson (JNJ), a healthcare bellwether, announced that the FDA has approved a label expansion for its oral pulmonary arterial hypertension (PAH) medicine, Tracleer.

  • Benzinga9 months ago

    Johnson & Johnson Shares Might Break Lower Before They Break Out

    Just a day after Credit Suisse reinstated an Outperform rating on Johnson & Johnson (NYSE: JNJ ) based on future gain from Actelion, BTIG and Atlantic Equities downgraded the stock from Neutral to Sell ...

  • Benzinga9 months ago

    Johnson & Johnson Shares Strong Since Actelion Acquisition, But Potential For Upside Remains

    Johnson & Johnson (NYSE: JNJ ) shares are up about 20 percent since the company acquired Actelion back in January. However, despite the strong performance, Credit Suisse analyst Vamil Divan sees more upside ...

  • J&J sees sales growth in near-term; raises 2017 profit forecast
    Reuters9 months ago

    J&J sees sales growth in near-term; raises 2017 profit forecast

    J&J, which reported better-than-expected quarterly earnings and raised its full-year profit forecast on Tuesday, is banking on newer pharmaceuticals to counter slowing demand for some of its older, best-selling products, including Remicade and diabetes drug Invokana. J&J's shares were up 1.9 percent at $134.64 in afternoon trading on the New York Stock Exchange. Chief Executive Alex Gorsky said that when drugs add months or years to patient lives and make significant differences on health outcomes, as with multiple myeloma treatment Darzalex and leukemia drug Imbruvica, the company has experienced less pricing pressure.

  • 4 Things That Matter When Johnson & Johnson Reports Its Second-Quarter Results
    Motley Fool9 months ago

    4 Things That Matter When Johnson & Johnson Reports Its Second-Quarter Results

    Headline figures aside, this is what investors should really be paying attention to when J&J reports on Tuesday, July 18.

  • Reuters10 months ago

    Actelion spin-off Idorsia's shares rise 30 pct in market debut

    Shares in Idorsia, the drug pipeline firm spun off from biotech group Actelion after Johnson & Johnson's $30 billion takeover, rose nearly 30 percent after making their market debut at 10 Swiss francs ...

  • Reuters10 months ago

    Actelion spin-off Idorsia makes market debut at 10 Sfr per share

    Shares in Idorsia, the drug pipeline company spun off from biotech group Actelion after Johnson & Johnson's $30 billion takeover, made their market debut at 10 Swiss francs per share on Friday. One trader said the stock had been trading over the counter this week at around 8 francs, the theoretical price given the difference between Actelion's share price in Swiss francs and the $280 cash price J&J is paying for Actelion.